A PHASE 1b STUDY OF ZN-c3 IN COMBINATION WITH CHEMOTHERAPY OR BEVACIZUMAB IN SUBJECTS WITH OVARIAN, PERITONEAL, OR FALLOPIAN TUBE CANCER
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.
Why this Research Matters
This study plans to learn more about an investigational drug called ZN-c3 (also known as azenosertib; KP-2638). Investigational means that the study drug has not been approved by the U.S. Food and Drug Administration (FDA). ZN-c3 may be called the study d
Who can Participate
Detailed eligibility criteria is available on clinicaltrials.gov. These requirements will be discussed with your doctor and/or study representative. Click the NCT number link below to learn more about this study on ClinicalTrials.gov
Study ID
Protocol Number: 22-0890
More information available at ClinicalTrials.gov: NCT04516447
Meet the Team
Principal Investigator